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the argument for screening for colorectal carcinomas and discuss the means available and the
implications ofimplementing screening programmes using some ofthese methods. A suggestion
is made for the more rational use oflimited resources to target those at greatest risk.
INTRODUCTION
It is a humbling fact that, despite advances in
medical knowledge and improved anaesthetic
and surgical techniques, mortality rates for
patients diagnosed as having colorectal cancer
have changed little in the past three decades.'
This reflects the advanced stage at time of
diagnosis in many cases. It is accepted that the
prognosis is dependent on the age ofthe patient,
the differentiation ofthe tumour and the depth of
invasionatthetimeofdiagnosis.2Tumourswhich
are restricted to the bowel wall (Dukes' A) are
associated with a five year survival of 80%.
These however account for less than 10% of
colorectallesions. 3' IThelowoccurrenceofearly
tumours represents afailure topreventcolorectal
carcinomas. Prevention may be primary, where




in the aetiology ofcolorectal carcinoma, while a
highintakeofvegetablefibreisbelievedtoprotect
against tumour development.6'7 To implement
primary prevention would require re-education
ofthe population, with major changes in dietary
habits and benefits would not become apparent
for many years.
Before screening canbeconsidered as ameans of




b) an acceptable treatment must be available
c) prognosis must be improved by early
detection
d) the incidence of the disease must be high
enough to justify the cost of screening
e) an acceptable screening test must be
available; this should be cheap, reliable,
have a high degree of sensitivity and
specificity and be acceptable to the
population being screened.5'8
Colorectal cancerfulfilsmany ofthesecriteria. It
isthesecondleadingcauseofcancerdeathsinthe
United States ofAmericaandGreatBritain. Over
20,000newcases werediagnosedinEngland and
Wales in 1983, and 1,138 cases were diagnosed
in Northern Ireland during 1991-92 giving an
incidenceof35.8/100,000ofthepopulation.9"10" 11
As has been mentioned earlier, prognosis is
improvediftumours aredetectedwhenrestricted
to the mucosa. It is now accepted that most
carcinomasdevelop fromadenomatouspolyps as
suggested by Morson and colleagues.'2 In theory
colorectal cancer could be prevented by the
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detection of adenomatous polyps in the
premalignant phase. Many ofthese are amenable
to endoscopic removal, increasing the accept-
ability of the treatment available.
At present the criterion which colorectal cancer
fails to fulfil is the availability of an acceptable






v) double contrast barium enema (DCBE)
vi) colonscopy
vii) faecal occult blood testing (FOBT)
Each of these has varying sensitivity and
specificityand, astheinvestigationsbecomemore
invasive, increasing morbidity and mortality.
QUESTIONNAIRE
Several studies have been undertaken to
investigate the efficiency of a questionnaire in
detecting colorectal neoplasia.'3' 14, 15 In using
questionnaires it is possible to detect only those
patients who are symptomatic and here one must
assume that lesions will cause symptoms at an
early premalignant stage of the disease. This is
not supported by the presentation of colorectal
neoplasiawith upto 25% ofthosewithcolorectal
carcinoma having disseminated disease at the
time of diagnosis.16 17 In addition the high
incidence of colonic symptoms in normal
individuals or individuals with benign disease
makes the specificity of questionnaires
unacceptably low. 13, 14
DIGITAL EXAMINATION
Digitalexamination whilebeingcheap andeasily
performed fails both in acceptability and
sensitivity, with approximately 10% of colonic




shouldbe visible with arigid sigmoidoscope (i.e.
up to 25 cms).21'22 In practice the instrument is
rarely inserted to 25 cms and the view is often
obscured by faeces.'9'23 Screening programmes
usingrigidsigmoidoscopy havedetected tumours
in less than 0.2% of those screened.24 The
University ofMinnesotaCancerDetectionCenter
has shown the benefits ofrigid proctosigmoido-
scopy claiming an 85% reduction in the
statistically anticipatedadenocarcinomas inthose
undergoingtheexaminationroutinely.25 However
the costs of such a screening programme are
prohibitive with figures from the United States
suggesting that only one tumour is detected per
$70,000 expended.2
FLEXIBLE SIGMOIDOSCOPY
Flexible sigmoidoscopy has many advantages
overrigidsigmoidoscopy. Upto60cmsofrectum
and colon can be examined, with 50-70% of
polyps said to occurwithin this length ofcolon.20
The examination is said to cause less discomfort
than rigid sigmoidoscopy and can be performed
with a minimum of bowel preparation.
Interestinglytwostudieshaveshownnodifference
in detection ofpolyps whenusing a 35 cms scope
compared with the 60 cms instrument.2728 In
spite of these advantages compliance has been
poor in screening programmes using the flexible
scope.31 The positive predictive value is low;
between2-6% ofasymptomaticpatients screened
were found to have adenomas >1 cm in
diameter. 29,30
The disadvantages offlexible sigmoidoscopy are
the need for training of the endoscopist, the
capital outlay in providing the service and the
time required. It must also be noted when using
both flexible and rigid sigmoidoscopy that in
recent years several reports have documented an
increased incidence of right sided colonic
tumours. This so called "shift to the right" will
reduce the numberoftumours withinreach ofthe
sigmoidoscope and may reduce the efficacy of
this as a method of screening.32' 33
COLONOSCOPY
Colonoscopy provides the best opportunity for
evaluating the colonic mucosa, with sensitivities
and specificities of over 95% being achieved. It
may also be a therapeutic procedure enabling
pedunculated polyps to be removed. Its use as a
population screening test is prohibited by time,
expense and expertise required to perform the
examination, with even an experienced
endoscopist failing to reach the caecum in as
many as 20% of examinations. Being more
invasiveitisassociatedwithahighercomplication
rate with the risk of perforation reported as 1 in
500- 1 in l0,000.24'34~36 Perforation is associated
with a mortality of 5 10%o.36 It cannot be
recommended forscreening on apopulationbasis
C The Ulster Medical Society, 1997.Screeningfor Colorectal Cancer 3
but should be the method of choice in the high
risk groups.
BARIUM ENEMA
Barium enema has the advantage of permitting
visualisation of the colon and rectum at a lower
cost and with lowermorbidity and mortality than
colonoscopy. Criticisms of this as a population
screeningmethodincludethecost, thelackofany
therapeutic potential and the lower sensitivities
andspecificities whencomparedtocolonoscopy.
Double contrast barium enema can detect up to
90% ofcancers orpolyps over 1 cm indiameter.35
Single contrast enema should be condemned as a
screeningtestachieving sensitivities ofonly0.41
for polyps and 0.7 for cancers.37
It must also be considered in the cost of the
examination that should it prove positive then
endoscopy may be required if polypectomy is
considered. Barium enema alone is also an
inadequate examination of the colorectum and
should be combined with at least rigid
sigmoidoscopy to improve visualisation of the
rectosigmoid junction.
FAECAL OCCULT BLOOD TESTING
FOBT is often used as a preliminary diagnostic
test in those presenting with non-specific
abdominal symptoms. It is also used in elderly
patients in whom it is considered advisable to
avoid more invasive tests if possible.
The basis ofthe test is not the detection ofblood
inthe stool butratherthe detection ofanelevated
faecal blood level. It has been calculated that the
median daily blood loss into the gut for normal
subjects is 0.6-1.2 ml/day which is equivalent to
a faecal haemoglobin concentration of <2 mg/g
of faeces2038,39
Bleedingfromcolorectalcancershasbeen shown
to range from 0 to 75 ml/day with a median loss
of 1.2 ml/day being recorded.38 39 40
The basis ofmost chemical tests is the oxidation
of phenolic compounds by the addition of
hydrogenperoxide. Thisiscatalysedbyhaematin,
a breakdown of haemoglobin in the gastro-
intestinal tract. Compounds such as benzidine,
orthotolidine or most commonly guaiac react
withhydrogenperoxidasetogiveacolourchange.
To avoid false positives from substances similar
to haematin (e.g. animal haemoglobin) it is
recommended that a meat free, high fibre diet is
taken for three days prior to testing. Other foods
suchas turnips, horseradish, salmon and sardines
are also to be avoided.
The test is repeated over three consecutive days
to account forvariable blood loss. Stoehlein and
colleagues reportthat ablood loss ofgreaterthan
10 ml per day will result in a positive FOBT in
90% ofcases, while Hardcastle suggested a loss
of20 ml per day will result in a positive result in
89-90% of cases20 41 The sensitivity of the test
can be further increased by prolonging the
duration of the test from 3-6 days and by
rehydrating the slides of faeces before
testing.42'43'44 However the decrease in false
negativerateresultsinanincreaseinfalsepositive
rate, and with this afall in the positive predictive
value.
There are howeverproblems with the test, in that
in order for the reaction to occur degradation of
haemoglobin is required. If, in the case of left
sided lesions the blood has not been degraded
thenthetestmaynegative, whileincaecallesions
excessive degradation may occur, destroying the
haematin required to catalyse the reaction, thus
resulting in anegative FOBT. Itis recognised for
these reasons that caecal and rectal tumours may
not be detected by FOBT.45'46 Attempts to
eliminate the effects ofdiethave been made with
the Haemoquant test designed to detect the
conversion of haem to fluorescent porphyrins
thuseliminatingtheeffectsofdietaryperoxidases.
Ithas the addedadvantage ofbeing aquantitative
test, permitting an estimation ofthe origin ofthe
blood loss to be made since the total amount of
haemoglobin and degraded haemoglobin can be
measured.47
Immunological tests detecting human
haemoglobin only have been developed. These
are extremely sensitive, detecting haemoglobin
in a concentration of 0.3 mg/g of faeces.48 Such
tests have increased detection of blood in the
stool by up to 25% in comparison with the
Haemoccult test. These tests are however more
expensive and difficult to perform.50 51'52 A
combination test with the immunological
component being performed only ifthe chemical
test proves positive has been suggested.49
To determine if FOBT is of benefit five major
controlledtrials havebeenundertaken. 5 s s' 57
58,59,60 To eliminate problems with length bias
(i.e. better differentiated tumours are present in
the community longer and are therefore more
likely to be detected by screening), leadtime bias
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TABLE I
Summary offive major trials ofFaecal Occult Blood Testfor screeningfor colorectal carcinoma.
Study Size Compliance Positive Test Positive Predictive Value
Minnesota 46,000 80% 1st year 1.8-3.5% Invasive Ca. 29%
70% later Polyps 8%
Memorial
Sloan >20,000 74% 2.4% 12%
Kettering 38%
Danish
Study 60,000 67% 1.1% 17%
41%
Swedish
Study 27,700 66% 1.9-5.8%
Nottingham
Study 100,000 52% 2.3% 11%
23%
(i.e.prolongationofsurvivalisattributedtoearlier
diagnosis with death occurring at the same time)
and selection bias (i.e. well motivated, health
conscious, individuals are more likely to
participate in screening programmes) it is
necessary to compare morbidity and mortality of
agroup offered the screening testwith an age sex
matched group who are not screened.
The results are summarised in Table I. At best
compliance is ofthe order of70% falling as low
as 52% in the early stages of the Nottingham
trial.8 Results regarding survival advantage are
becoming available. The percentage ofDukes' A
tumours in the screened groups is higher than in
the control groups and as one would anticipate a
survival advantage is being demonstrated in the
screen-detected groups with Dukes' A and B
tumours.61s62
This is not the only criterion on which the
feasibility of performing screening will be
assessed. The cost of implementing such a
programme is a major factor. Offering the
screening test to those aged 50-65 years and
assuming apositive FOB rate of2% would result
in approximately 1,250 colonoscopy examin-
ations per million ofthepopulation assuming the
percentage ofthoseaged50-65 remains constant.
The cost would then increase as positive
examinations required further endoscopy.
Due to a lack of controlled trials it has been
necessary to resort to an elaborate mathematical
model. A number of screening strategies have
been considered incorporating a combination of
procedurese.g. FOBTandsigmoidoscopy, FOBT
and DCBE and FOBT and colonoscopy. The
decrease in probability of developing colorectal
cancer, increase in life expectancy and cost have
been calculated.63 64'65 The authors stress that
each strategy must be compared in terms of
efficiency, cost and inconvenience. The results
suggestthatannualFOBTmightreducemortality
by 30% while annual colonoscopy could reduce
mortality by 85%.66 It is also suggested that
annual FOBT combined with either 5 yearly
DCBE or colonoscopy preserves 70-90% of the
effectivenessofannualcolonoscopicexamination
while reducing costs by 80%.66
The dilemma with which we are faced is that
while preliminary results from controlled trials
and mathematical models suggest that screening
may be effective the cost of performing such a
screening programme would be enormous. The
numbers requiring endoscopy/DCBE following
positive FOBT would necessitate a major
expansion in the existing services.
A more rational use of limited resources would
be the targeting of those at greatest risk. This
wouldincludethosewithageneticpredisposition
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to cancer, and those with a long standing history
of colitis.
Familial adenomatous polyposis which
encompasses the diseases familial polyposis coli
andGardner'ssyndromeisanautosomaldominant
condition characterised by the development of
more than 100 adenomatous polyps in the colon
andrectum. Ifnottreatedappropriatelymalignant
change inevitably develops in one or more of
thesepolyps.Thegeneticdefecthasbeenlocalised
to chromosome 5. This has permitted genetic
screening of those at risk, initially by linkage
analysis but more recently by direct sequencing
of the gene and mutation analysis. Northern
Ireland has a high prevalence of familial
adenomatouspolyposiswithanestimated93from
26familieshavinga 1 in2riskofhavinginherited
the gene with a further 49 with a risk of 1 in 4.67
Prior to DNA analysis, screening ofthose at risk
was performed by regular sigmoidoscopic
examination ofthe rectum. Such is the accuracy
of DNA analysis that many of those at risk can
either be eliminated or have the frequency ofthe
endoscopic examinations greatly reduced.
Colonoscopy canbereservedforthose atgreatest
risk to monitor the colon and determine the
optimum time for surgical intervention.
In contrast to FAP, hereditary non-polyposis
colorectal cancer (HNPCC) lacks a readily
identifiable premalignant marker ofthe disease.
Thediagnosis is dependent on an accurate family
history which often is not available. The
penetrance ofthe gene is 70-80%. These factors
may make it difficult to label a family as an
HNPCC kindred with confidence. HNPCC
families are said to account for 2-5% of all
colorectaltumours,althoughpublisheddatawould
suggest that in Northern Ireland the incidence is
at the lower end of the spectrum.68 To date 4
genes have been implicated in HNPCC, thus
making DNA analysis more difficult.68 Unlike
FAP in which DNA analysis is well established
the mainstay of screening HNPCC families
remainsidentificationoffamilies atriskfollowed
by regular visualisation of the colon. It is
recommended that HNPCC kindred members
undergo 3-yearly colonoscopy beginning at 25
years of age although some would suggest that
this should be increased to annual examination
after 35 years of age.69'70
There are also a number of families who while
failing to fulfil the strict criteria for an HNPCC
kindred undoubtedly have an increased risk (see
Tables II and III). We would recommend that
patients in whomthe life timeriskis increased to
greater than 1 in 10 be included in the screening
programme.
The final group with an increased risk of
developing colorectal carcinoma arethosewith a
longstanding history of colitis. The association
between ulcerative colitis and carcinoma is well
establishedinthosewithapancolitis,poorcontrol,
and disease ongoing for greater than 10 years.
Gyde and colleagues reported an 8-fold increase
TABLE II
Amsterdam criteriafor diagnosis ofHereditary
Non-polyposis Colorectal Cancer (HNPCC)
kindreds
i) Three ormorerelatives with histologically
verifiedcolorectalcancer,oneofthembeing
a first degree relative of the other two.
ii) Atleasttwoconsecutivegenerationsshould
be affected.
iii) In one of the relatives colorectal cancer
should be diagnosed at under 50 years of
age.
(Vassen H F, Mecklin J-P, Meera Khan P, Lynch H T.
The international collaborative group on hereditary non-
polyposis colorectal cancer (ICG-HNPCC)
Dis Colon Rectum 1991; 34: 424-5)
TABLE III
Cancer risk infirst degree relatives ofpatients
with colorectal carcinoma
Population risk 1 in 50
One relative affected
(any age) 1 in 17
One first degree &
one second degree 1 in 12
One relative under 45 affected 1 in 10
Two first degree relatives
affected lin6
Dominant pedigree 1 in 2
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in risk ofdeveloping colorectal cancer in agroup
ofover 200 patients with ulcerative colitis when
compared with the general public. Within this
group those with extensive colitis had a 19-fold
increase in risk of developing malignancy.7'
We believe screening of these high-risk groups
represents the best use of limited resources.
Implementation of a population screening
programme using FOBT would require an
enormous expansion ofendoscopy services for a
very low yield in terms of significant pathology
detected per thousand patients screened.
Colonoscopy of high-risk groups would require
minimalexpansionofexistingendoscopyservices
and has the potential for identifying up to 10% of
colorectalcarcinomataatanearlystage, orindeed
preventing their development by detection of
premalignant adenomas.
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